Hybrid Closed-Loop Systems Help Adults with Type 1 Diabetes Spend More Time in Target Range

Researchers followed 23 adults with Type 1 diabetes who started using the MiniMed 780G hybrid closed-loop system between September and December 2024. A hybrid closed-loop system uses a continuous glucose monitor, insulin pump, and algorithm that work together to automatically adjust insulin delivery based on blood sugar readings.

The study tracked several measures of glycemic control: time in range (TIR), time in tight range (TITR, defined as 70–140 mg/dL), average glucose levels, glucose variability, time above range, time below range, and daily insulin doses. Researchers collected data for 14 days before starting the system, during the first 14 days after starting it, and again at 3 months.

At 3 months, users of the MiniMed 780G spent 13% more time in range and 12.2% more time in the tight target range compared to before starting the system. These improvements were statistically significant, meaning they were unlikely to be due to chance.

The benefits appeared quickly. Within just 2 weeks, users were already seeing improvements in time in range and other measures. This suggests the system adapts to individual needs relatively fast after initiation.

Beyond time in range, average blood glucose fell by 16.7 mg/dL, and glucose variability decreased—meaning blood sugar was more stable and predictable throughout the day.

The study included two groups: 4 people who had been using multiple daily injections (MDI) before switching to the system, and 19 who had already been using insulin pumps. Researchers explored whether prior insulin delivery method affected outcomes.

People who switched from MDI to the hybrid closed-loop system saw similar glycemic improvements to those who had been pump users, suggesting the system provides meaningful benefit regardless of prior treatment approach.

This real-world evaluation supports the growing body of evidence that hybrid closed-loop systems can help adults with Type 1 diabetes achieve tighter glycemic control. Tight glycemic range (70–140 mg/dL) is being recognized as an important marker of near-normal blood sugar management.

The study reflects routine clinical practice—not a controlled trial—which means these results reflect what people might expect when using the system in everyday life. However, as a single-center study with a relatively small group, these findings should be viewed as one piece of a larger picture of evidence about hybrid closed-loop systems.

Source: Current diabetes reviews. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.